

Tricia Tan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/417938/tricia-tan-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

2,629
citations

29
h-index

48
g-index

140
ext. papers

3,322
ext. citations

7.1
avg, IF

5.19
L-index

#	Paper	IF	Citations
122	The clinical outcomes, appetite and metabolic effects of sleeve gastrectomy and Roux-en-Y gastric bypass: A comparative review. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022 , 22, 100315	1.7	0
121	The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	0
120	H NMR Signals from Urine Excreted Protein Are a Source of Bias in Probabilistic Quotient Normalization.. <i>Analytical Chemistry</i> , 2022 , 94, 6919-6923	7.8	
119	A glucagon analogue decreases body weight in mice via signalling in the liver. <i>Scientific Reports</i> , 2021 , 11, 22577	4.9	1
118	Preserved C-peptide in survivors of COVID-19: post-hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	4
117	Comparison of Diabetic Ketoacidosis in Adults During the SARS-CoV-2 Outbreak and Over the Same Time Period for the Preceding 3 Years. <i>Diabetes Care</i> , 2021 , 44, e29-e31	14.6	7
116	Surpassing insulin glargine in type 2 diabetes with tirzepatide. <i>Lancet, The</i> , 2021 , 398, 1779-1781	40	0
115	Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. <i>Diabetes Care</i> , 2021 , 44, 614-617	14.6	1
114	Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1471-1483	6.7	2
113	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021 , 320, E671-E679	6	1
112	Synacthen Stimulation Test Following Unilateral Adrenalectomy Needs to Be Interpreted With Caution. <i>Frontiers in Endocrinology</i> , 2021 , 12, 654600	5.7	0
111	Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2208-2220	5.6	15
110	Weight Loss by Low-Calorie Diet Versus Gastric Bypass Surgery in People With Diabetes Results in Divergent Brain Activation Patterns: A Functional MRI Study. <i>Diabetes Care</i> , 2021 , 44, 1842-1851	14.6	3
109	Tirzepatide and the new era of twincretins for diabetes. <i>Lancet, The</i> , 2021 , 398, 95-97	40	1
108	Imperial Satiety Protocol: A new non-surgical weight-loss programme, delivered in a health care setting, produces improved clinical outcomes for people with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 270-275	6.7	0
107	The Effect of Standard Versus Longer Intestinal Bypass on GLP-1 Regulation and Glucose Metabolism in Patients With Type 2 Diabetes Undergoing Roux-en-Y Gastric Bypass: The Long-Limb Study. <i>Diabetes Care</i> , 2021 , 44, 1082-1090	14.6	7
106	Genetic and biased agonist-mediated reductions in β -arrestin recruitment prolong cAMP signaling at glucagon family receptors. <i>Journal of Biological Chemistry</i> , 2021 , 296, 100133	5.4	18

105	Thyroid Function Before, During, and After COVID-19. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e803-e811	5.6	69
104	Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	29
103	Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021 , 8, 1-54	1.7	4
102	The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism. <i>Endocrine Connections</i> , 2021 , 10, R66-R76	3.5	2
101	Who will benefit from bariatric surgery for diabetes? A protocol for an observational cohort study. <i>BMJ Open</i> , 2021 , 11, e042355	3	1
100	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 47	9	14
99	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. <i>Biochemical Pharmacology</i> , 2021 , 190, 114656	6	1
98	Changes in circulating kisspeptin levels during each trimester in women with antenatal complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	3
97	The metabolomic effects of tripeptide gut hormone infusion compared to Roux-en-Y gastric bypass and caloric restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	3
96	Performance of plasma kisspeptin as a biomarker for miscarriage improves with gestational age during the first trimester. <i>Fertility and Sterility</i> , 2021 , 116, 809-819	4.8	5
95	Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. <i>Molecular Metabolism</i> , 2021 , 51, 101242	8.8	2
94	Improving the Interpretation of Afternoon Cortisol Levels and SSTs to Prevent Misdiagnosis of Adrenal Insufficiency. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab147	0.4	0
93	Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. <i>Molecular Metabolism</i> , 2021 , 53, 101296	8.8	1
92	Thyrotoxic periodic paralysis presenting as a broad complex tachycardia.. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021 , 82, 1-3	0.8	
91	Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome. <i>Current Diabetes Reports</i> , 2020 , 20, 26	5.6	9
90	Association between high serum total cortisol concentrations and mortality from COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 659-660	18.1	110
89	Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	6
88	Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	8

87	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. <i>Journal of Endocrinology</i> , 2020 , 246, R65-R74	4.7	9
86	1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model. <i>Diabetes</i> , 2020 , 69, 1798-P	0.9	
85	Adrenal Vein Sampling: Radiation Dose Reduction on New Angiography Platform. <i>The Arab Journal of Interventional Radiology</i> , 2020 , 4, 102-106	0.1	
84	Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	13
83	Cortisol concentrations and mortality from COVID-19 - AuthorsSreply. <i>Lancet Diabetes and Endocrinology,the</i> , 2020 , 8, 809-810	18.1	2
82	Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
81	Candy cane revision after Roux-en-Y gastric bypass. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020 , 34, 2076-2081	5.2	3
80	The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 345-360	5.9	20
79	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. <i>Diabetes Care</i> , 2019 , 42, 1446-1453	14.6	47
78	Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 549-559	18.1	50
77	Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019 , 7, 987-989	0.7	2
76	Metabolic Changes and Diabetes Microvascular Complications 5Years After Obesity Surgery. <i>Obesity Surgery</i> , 2019 , 29, 3907-3911	3.7	9
75	Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. <i>Expert Opinion on Drug Discovery</i> , 2019 , 14, 1151-1159	6.2	8
74	SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
73	2308-PUB: Liraglutide 3 mg for Weight Loss in a Real-World Setting: Clinical Outcomes after 56 Weeks. <i>Diabetes</i> , 2019 , 68, 2308-PUB	0.9	
72	390-P: Changes in Glycaemic Variability after RYGB: A One-Year Prospective Study with Comparison to Patients with Post-bariatric Hypoglycaemia. <i>Diabetes</i> , 2019 , 68, 390-P	0.9	
71	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1498-1501	6.7	35
70	Cracking the combination: Gut hormones for the treatment of obesity and diabetes. <i>Journal of Neuroendocrinology</i> , 2019 , 31, e12664	3.8	17

69	Targeting GLP-1 receptor trafficking to improve agonist efficacy. <i>Nature Communications</i> , 2018 , 9, 1602	17.4	88
68	Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 269-270	18.1	1
67	Oxyntomodulin analogue increases energy expenditure via the glucagon receptor. <i>Peptides</i> , 2018 , 104, 70-77	3.8	23
66	Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 516-522	8.9	39
65	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. <i>Frontiers in Endocrinology</i> , 2018 , 9, 442	5.7	12
64	The effects of kisspeptin on β -cell function, serum metabolites and appetite in humans. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2800-2810	6.7	39
63	Of Mice Not Men? Actions of Interleukin-6 on Glucose Tolerance. <i>Cell Metabolism</i> , 2018 , 27, 1157-1158	24.6	4
62	Beyond Weight Loss: Establishing a Postbariatric Surgery Patient Support Group-What Do Patients Want?. <i>Journal of Obesity</i> , 2018 , 2018, 8419120	3.7	13
61	Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases. <i>Endocrinology</i> , 2017 , 158, 1755-1765	4.8	9
60	RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. <i>Endocrinology</i> , 2017 , 158, 2680-2693	4.8	20
59	Development of a UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon and dosed GLP-1 from human plasma. <i>Bioanalysis</i> , 2017 , 9, 733-751	2.1	9
58	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2364-2372	5.6	55
57	Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. <i>European Journal of Endocrinology</i> , 2017 , 177, 455-464	6.5	29
56	Redefining the stress cortisol response to surgery. <i>Clinical Endocrinology</i> , 2017 , 87, 451-458	3.4	32
55	Limitations of the DiaRem Score in Predicting Remission of Diabetes Following Roux-En-Y Gastric Bypass (RYGB) in an ethnically Diverse Population from a Single Institution in the UK. <i>Obesity Surgery</i> , 2017 , 27, 782-786	3.7	20
54	The preanalytical stability of glucagon as measured by liquid chromatography tandem mass spectrometry and two commercially available immunoassays. <i>Annals of Clinical Biochemistry</i> , 2017 , 54, 293-296	2.2	6
53	Clinical roles in clinical biochemistry: a national survey of practice in the UK. <i>Annals of Clinical Biochemistry</i> , 2017 , 54, 370-377	2.2	2
52	Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. <i>Journal of Investigative Surgery</i> , 2017 , 30, 162-169	1.2	1

51	Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. <i>Journal of applied laboratory medicine, The</i> , 2016 , 1, 152-161	2	22
50	Gastrointestinal hormones and their role in obesity. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016 , 23, 18-22	4	26
49	Peptide receptor radionuclide therapy for metastatic paragangliomas. <i>Medical Oncology</i> , 2016 , 33, 47	3.7	33
48	Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 72-81	6.7	81
47	Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1520-8	5.6	11
46	Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S28	4.0	3
45	Learning curve of vessel cannulation in rats using cumulative sum analysis. <i>Journal of Surgical Research</i> , 2015 , 193, 69-76	2.5	3
44	Identification of plasma protease derived metabolites of glucagon and their formation under typical laboratory sample handling conditions. <i>Rapid Communications in Mass Spectrometry</i> , 2015 , 29, 171-81	2.2	2
43	Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones. <i>Postgraduate Medicine</i> , 2015 , 127, 494-502	3.7	14
42	The future role of gut hormones in the treatment of obesity. <i>Therapeutic Advances in Chronic Disease</i> , 2014 , 5, 4-14	4.9	90
41	Can Bayliss and Starling gut hormones cure a worldwide pandemic?. <i>Journal of Physiology</i> , 2014 , 592, 5153-67	3.9	5
40	Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. <i>Diabetes</i> , 2014 , 63, 3711-20	0.9	92
39	Gut hormones and Type 2 diabetes mellitus. <i>Diabetes Management</i> , 2014 , 4, 501-513	0	2
38	Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2317-24	5.6	24
37	An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. <i>British Journal of Cancer</i> , 2014 , 110, 115-22	8.7	41
36	Multicentre study of investigation and management of inpatient hyponatraemia in the UK. <i>Postgraduate Medical Journal</i> , 2014 , 90, 694-8	2	19
35	Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma. <i>Bioanalysis</i> , 2014 , 6, 3295-309	2.1	16
34	Gut hormones as therapeutic agents in treatment of diabetes and obesity. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 996-1001	5.1	42

33	Analogues of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active. <i>Peptides</i> , 2013 , 39, 6-10	3.8	14
32	Treating the obese diabetic. <i>Expert Review of Clinical Pharmacology</i> , 2013 , 6, 171-83	3.8	6
31	Gut hormones and obesity: physiology and therapies. <i>Vitamins and Hormones</i> , 2013 , 91, 143-94	2.5	16
30	Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. <i>Diabetes</i> , 2013 , 62, 1131-8	0.9	134
29	Immunohistochemical markers of the hypoxic response can identify malignancy in pheochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. <i>British Journal of Cancer</i> , 2013 , 108, 429-37	8.7	35
28	Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism. <i>Clinical Endocrinology</i> , 2013 , 78, 738-42	3.4	9
27	PYY 2013 , 1160-1165		
26	Pancreatic Polypeptide 2013 , 1294-1299		2
25	Minireview: Glucagon in stress and energy homeostasis. <i>Endocrinology</i> , 2012 , 153, 1049-54	4.8	83
24	The role of the gut/brain axis in modulating food intake. <i>Neuropharmacology</i> , 2012 , 63, 46-56	5.5	107
23	A man with anxiety, confusion, and red eyes. <i>BMJ, The</i> , 2012 , 345, e4443	5.9	2
22	Adrenal venous sampling as a diagnostic procedure for primary hyperaldosteronism: experience from a tertiary referral centre. <i>Hormones</i> , 2012 , 11, 151-9	3.1	11
21	A comparison of the performance of ⁶⁷ Ga-DOTATATE PET/CT and ¹¹¹ In-MIBG SPECT in the diagnosis and follow-up of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1266-70	8.8	87
20	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 232-9	3.8	26
19	Emerging therapies in the treatment of ² diabetes ³ beyond GLP-1. <i>Trends in Pharmacological Sciences</i> , 2011 , 32, 8-15	13.2	32
18	⁶⁸ Ga-DOTA-TATE PET vs. ¹²³ I-MIBG in identifying malignant neural crest tumours. <i>Molecular Imaging and Biology</i> , 2011 , 13, 769-75	3.8	82
17	A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36. <i>Endocrinology</i> , 2011 , 152, 4630-40	4.8	18
16	Insulin-mediated "pseudoacromegaly". <i>Hormones</i> , 2011 , 10, 156-61	3.1	8

15	Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. <i>Clinical Endocrinology</i> , 2010 , 73, 369-74	3.4	47
14	Familial adenomatous polyposis and hypertension. <i>Lancet, The</i> , 2010 , 375, 1752	4.0	2
13	Gut-brain cross-talk in appetite regulation. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2010 , 13, 588-93	3.8	14
12	Hormonal interactions between gut and brain. <i>Discovery Medicine</i> , 2010 , 10, 543-52	2.5	29
11	MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress. <i>Clinical Endocrinology</i> , 2009 , 70, 340-1	3.4	8
10	High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy. <i>Clinical Endocrinology</i> , 2009 , 70, 812-3	3.4	12
9	The pursuit of beauty. <i>Lancet, The</i> , 2008 , 371, 596	4.0	5
8	The obesity epidemic: pharmacological challenges. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2008 , 8, 82-98		44
7	A case of severe hyponatraemia. <i>BMJ, The</i> , 2008 , 337, a2377	5.9	
6	Pituitary macroadenomas: are combination antiplatelet and anticoagulant therapy contraindicated? A case report. <i>Journal of Medical Case Reports</i> , 2007 , 1, 74	1.2	9
5	Vitamin D status in patients with osteopenia or osteoporosis--an audit of an endocrine clinic. <i>International Journal for Vitamin and Nutrition Research</i> , 2006 , 76, 307-13	1.7	10
4	Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4162-5	5.6	101
3	Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. <i>Journal of Biological Chemistry</i> , 2003 , 278, 8877-80	5.4	103
2	Inhaled insulin in type 1 diabetes. <i>Lancet, The</i> , 2001 , 357, 1979	4.0	5
1	Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling		1